Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETCat01: Neoadjuvant Epirubicin, Docetaxel, and Carboplatin in Primary Breast Cancer
NCT00527449Phase 2Completed
- Sponsor
- Asklepios Klinik Weißenfels
- Start
- May 2006
- Primary completion
- Sep 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of epirubicin, carboplatin and docetaxel in breast cancer, sponsored by Asklepios Klinik Weißenfels. Primary endpoint: Pathologic Complete Remission. Started May 2006; status: completed.
02
Drugs
epirubicincarboplatindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00527449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527449.